To help Asia-Pacific emerging biopharmaceutical companies achieve their growth aspirations, Quintiles has launched a new solution set tailored to meet the needs of emerging companies in the world’s most diverse and dynamic healthcare market.
“Asia-Pacific is poised to become the world’s next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines,” said Senior Vice President Ross Horsburgh, M.D., Quintiles Head of Clinical Development, Asia-Pacific. “These companies face formidable challenges as they look to expand into markets or therapeutic areas in which they may have limited or no experience.
“From start-ups to larger emerging players, our Asia-Pac solution is designed to improve their probability of success, whether their growth aspirations are regional or global.”
The Quintiles Asia-Pacific Emerging Biopharma solution includes:
• Dedicated local project leadership based in Asia-Pac with knowledge of local markets, customs and language.
• Custom-tailored operational models to meet individual customer priorities and use Quintiles’ world-class processes and platforms.
• Accelerated patient recruitment through our global network of 25 Prime and >1,200 Partner sites - with seven of those Prime Sites located in Asia-Pacific.
The Asia-Pacific solution gives emerging companies access to Quintiles’ data-driven insights; its knowledge of local markets; its in-depth therapeutic and scientific expertise; and its global drug development platform. It further adds to Quintiles’ solutions for emerging companies, which includes Novella Clinical, a specialty CRO focused on the needs of small to mid-sized oncology companies and medical device and diagnostic companies.
Quintiles is a recognized as an industry leader in Phase I and Phase II/III research among emerging biopharma customers. Since 2011 Quintiles has worked on more than 60 studies involving almost 20,000 patients for Asia-Pacific emerging companies. Quintiles is the recognized industry leader in the region, having won BioPharma Asia’s “Best CRO in Asia” award three times in the event’s five-year history, and in 2014 - for the sixth time in eight years - honored as Asia-Pacific CRO of the Year by Frost & Sullivan, a leading business research and consulting firm.